Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$739 Mln
Revenue (TTM)
$3 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.8 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
4.6
Industry P/E
24.51
EV/EBITDA
-2.5
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-1.4
Face value
--
Shares outstanding
149,055,879
CFO
$-461.46 Mln
EBITDA
$-526.01 Mln
Net Profit
$-537.26 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Annexon Inc (ANNX)
| 9.6 | -1.8 | 9.6 | 203.9 | 12.6 | -27.5 | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Annexon Inc (ANNX)
| -2.1 | 12.9 | -12.2 | -55.0 | -54.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Annexon Inc (ANNX)
|
5.5 | 739.3 | 3.4 | -207.0 | -6,361.1 | -102.2 | -- | 4.6 |
| 9.2 | 2,179.2 | 510.2 | 146.9 | 37.2 | 35.6 | 15.5 | 4.6 | |
| 12.5 | 3,812.0 | 3,018.8 | 72.1 | 12.6 | -80 | 54.3 | 86.1 | |
| 168.5 | 8,210.1 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 92.9 | |
| 73.2 | 13,446.3 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 42.5 | 4,055.0 | 761.4 | 99.7 | 7.3 | 15 | 46.5 | 5.7 | |
| 23.1 | 11,653.6 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.8 | |
| 8.2 | 7,645.3 | 7,227.1 | 386.1 | 16.6 | 6.9 | 13.8 | 0.9 | |
| 199.6 | 3,841.5 | 268.1 | 124.5 | 60.0 | 13.5 | 31.5 | 4.0 | |
| 37.7 | 3,099.9 | 158.3 | -68.9 | -29.3 | -113 | -- | 69.3 |
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3... clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California. Address: 1400 Sierra Point Parkway, Brisbane, CA, United States, 94005 Read more
CEO, President & Director
Mr. Douglas Love Esq., J.D.
CEO, President & Director
Mr. Douglas Love Esq., J.D.
Headquarters
Brisbane, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Annexon Inc (ANNX) is $5.50 (NASDAQ) as of 02-Apr-2026 16:23 EDT. Annexon Inc (ANNX) has given a return of 12.62% in the last 3 years.
Since, TTM earnings of Annexon Inc (ANNX) is negative, P/E ratio is not available.
The P/B ratio of Annexon Inc (ANNX) is 4.58 times as on 31-Mar-2026, a 19 discount to its peers’ median range of 5.66 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-5.09
|
2.40
|
|
2023
|
-2.57
|
1.38
|
|
2022
|
-2.06
|
1.23
|
|
2021
|
-3.42
|
1.88
|
|
2020
|
-6.78
|
1.24
|
The 52-week high and low of Annexon Inc (ANNX) are Rs 7.18 and Rs 1.29 as of 03-Apr-2026.
Annexon Inc (ANNX) has a market capitalisation of $ 739 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Annexon Inc (ANNX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.14
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.